Posts on Jan 1970

NANBIOSIS Unit 6 Research Featured During ICMAB Scientific Advisory Board Visit

NANBIOSIS Unit 6 contributed to advanced nanomedicine research showcased at the ICMAB Scientific Advisory Board visit.

Barcelona, May 2026 — Researchers from Institut de Ciència de Materials de Barcelona (ICMAB-CSIC) recently presented a poster highlighting innovative developments in fluorescent nanovesicles, dendrimers, and organic nanoparticles for sensing and bioimaging during the visit of the institute’s Scientific Advisory Board (SAB). The visit formed part of the evaluation activities linked to the Severo Ochoa excellence accreditation awarded to ICMAB.

The poster showcased multidisciplinary research focused on the development of advanced nanomaterials for biomedical imaging, biosensing, and diagnostic applications. Among the technologies presented were highly stable fluorescent quatsomes for bioimaging and nucleic acid sensing, ultrabright nanoparticles for deep-tissue imaging, and multifunctional dendrimers combining fluorescent and magnetic resonance imaging (MRI) capabilities.

Part of this research was carried out with the support of NANBIOSIS Unit 6, whose contribution was acknowledged in the poster. The Scientific Director of NANBIOSIS, Ramón Martínez Máñez, also participated in the Scientific Advisory Board committee involved in the visit.

The work reflects the growing impact of nanotechnology and advanced biomaterials in the development of next-generation biomedical imaging and sensing tools. These innovative platforms could contribute to improved diagnostics, real-time monitoring, and future personalized medicine applications.

The poster included contributions from researchers affiliated with CIBER-BBN and ICMAB-CSIC, with several of the presented studies recently published in leading scientific journals in materials science and nanomedicine.

NANBIOSIS Unit 6: Advanced materials for health

The poster highlights the mission of NANBIOSIS Unit 6, located at ICMAB-CSIC and coordinated by Prof. Nora Ventosa. This Unit specializes in the development, characterisation, and scale-up of molecular biomaterials with applications in biomedicine.

Equipped with state-of-the-art facilities and operating under ISO 9001 quality standards, Unit 6 offers advanced technologies such as the DELOS-SUSP method, a compressed-fluid-based process for producing highly controlled micro- and nanostructured materials. Its unique capability to scale processes from laboratory to industrial levels supports both research and technology transfer.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Platinum Nanoparticles Boost Radiotherapy Effectiveness Against Cancer

Researchers from INMA and NANBIOSIS have developed ultrasmall platinum nanoparticles that significantly boost radiotherapy effectiveness against cancer.

Zaragoza, May 2026 — Researchers from the Aragon Nanoscience and Materials Institute (INMA), together with collaborators from Instituto de Salud Carlos III, Spanish National Cancer Research Centre (CNIO) and the University of Elche, have developed ultrasmall platinum nanoparticles capable of significantly enhancing the effectiveness of radiotherapy in cancer treatment.

The study, published in Advanced Functional Materials, demonstrates that platinum nanoparticles measuring just 2–3 nanometres act through a dual mechanism to attack tumours. On one hand, platinum amplifies the radiation effect, increasing DNA damage in cancer cells. On the other, the nanoparticles locally generate oxygen inside tumours, helping overcome tumour hypoxia — one of the main causes of resistance to radiotherapy.

The research was led by José Ignacio García-Peiró, Miguel Encinas, José Luis Hueso and Jesús Santamaría, all members of CIBER-BBN and Unit 9 of NANBIOSIS.

Experiments carried out in cell and animal models showed a strong reduction in tumour growth while using low radiation doses, without detecting systemic toxicity. The ultrasmall size of the nanoparticles also facilitates their elimination through the urinary system, improving biocompatibility and safety.

Although still at the proof-of-concept stage, this work represents a promising step toward more effective and targeted radiotherapy strategies in cancer treatment.

The full article, Ultrasmall Platinum Nanoparticles for Radiation-Enhanced Cancer Therapy, is available in Advanced Functional Materials.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Open Seminar Today at I3A: Prof. Jaap den Toonder on Microfluidic Technologies for Biomedical Innovation

Join today’s open seminar at I3A on microfluidic technologies for biomedical innovation, featuring Prof. Jaap den Toonder from TU Eindhoven.

Zaragoza, May 2026 — NANBIOSIS invites researchers, students, and professionals to attend today’s open seminar, “Microfluidic Technologies Enabling Novel Biomedical Applications,” presented by Prof. Jaap den Toonder from Eindhoven University of Technology (TU/e).

The seminar will take place today, May 6, at 12:30 PM in the I3A Seminar Room, Floor 2, Block 5, offering attendees the opportunity to explore how microfluidic technologies are advancing biomedical research and healthcare innovation.

Prof. den Toonder is Full Professor and Chair of the Microsystems section at Eindhoven University of Technology since 2013. He holds both his MSc in Applied Mathematics and PhD in Mechanical Engineering (both cum laude) from Delft University of Technology. Before joining TU/e, he worked at Philips Research Laboratories Eindhoven as Principal Scientist and Chief Technologist.

His research focuses on “making things work at small scales” by developing smart materials, innovative technological concepts, and advanced microfabrication methods for microsystems. These technologies support cutting-edge applications in health and wellbeing, particularly in microfluidic chips, organ-on-chip systems, biomedical microdevices, and soft microrobotics.

With more than 180 scientific publications, over 60 patents, and more than 65 invited lectures at international conferences, Prof. den Toonder is a leading figure in the field of microfluidics and microsystems engineering. He also serves as scientific advisor to six spin-off companies originating from his research group.

Among his major achievements, he founded and directs the Microfab/lab, a state-of-the-art TU/e facility dedicated to the fabrication and analysis of microfluidic devices, microsystems, and biological materials. He is also the recipient of two ERC Advanced Grants (2019 and 2025) and has been a Fellow of the Netherlands Academy of Engineering since 2023.

The seminar is organized by TME Lab and is open to all interested attendees.

This event represents an excellent opportunity for the broader scientific community to discover how microfluidic technologies are enabling next-generation biomedical applications, from personalized medicine to advanced disease models.

Event details:

• Speaker: Prof. Jaap den Toonder
• Title: Microfluidic Technologies Enabling Novel Biomedical Applications
• Date: May 6, 2026
• Time: 12:30 PM
• Location: I3A Seminar Room, Floor 2, Block 5
• Organizer: TME Lab
• Admission: Open seminar

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: